InventisBio (SH:688382) Zheng Quan Zhi Xing·2025-08-22 12:10Core Viewpoint - The report highlights the financial performance and operational challenges faced by InventisBio, emphasizing its ongoing drug development efforts and the risks associated with being a pre-revenue biotech company [1][3][4]. Financial Performance - The company reported a revenue of 19.16 million RMB for the first half of 2025, representing a 28.85% increase compared to 14.87 million RMB in the same period last year [3]. - The total profit for the period was a loss of 119.43 million RMB, an improvement from a loss of 214.22 million RMB in the previous year [3]. - The net assets attributable to shareholders decreased by 5.12% to 171.81 million RMB from 181.08 million RMB at the end of the previous year [3]. Research and Development Focus - InventisBio is focused on developing innovative drugs targeting major diseases such as cancer, metabolic disorders, and autoimmune diseases, with a commitment to addressing unmet clinical needs [5][19]. - The company has established various platforms for drug discovery and development, including target evaluation, molecular design, pharmacology, and clinical trial design [5][19]. - All products in the pipeline are self-developed, with global intellectual property rights, and collaborations with well-known pharmaceutical companies [7][19]. Product Pipeline - The company has two authorized products: - Befotertinib (BPI-D0316): An EGFR tyrosine kinase inhibitor for treating EGFR mutation-positive non-small cell lung cancer (NSCLC) [8][9]. - Gisoresib (D-1553): A KRAS G12C inhibitor for treating various cancers, including NSCLC and colorectal cancer, with ongoing international clinical trials [9][10]. - Other products in clinical trials include: - Taragarestrant (D-0502): An oral selective estrogen receptor degrader for ER-positive, HER2-negative breast cancer [12][16]. - D-0120: A URAT1 inhibitor for treating hyperuricemia and gout, showing promising results in clinical trials [14][19]. - D-2570: A selective TYK2 inhibitor for treating psoriasis and other autoimmune diseases, with favorable safety and efficacy profiles [16][19]. Market Position and Strategy - The company aims to enhance its market position and international competitiveness by focusing on innovative drug development and addressing significant clinical needs [5][19]. - InventisBio's operational model involves outsourcing non-core activities to third-party service providers while maintaining control over critical research and development processes [19].